Abstract
Aromatase inhibitors (AIs) have been utilized for a number of estrogen-modulated conditions, including hormone-sensitive breast cancer, endometriosis and ovulation induction. Some borderline ovarian tumors (BOT) are estrogen-receptor positive, and case reports suggest the use of AIs in the prevention of recurrent serous BOT. We present a case of progression from mucinous cystadenoma to mucinous BOT after two prior cystectomies in whom an AI was used and the patient is now 2 years without recurrent disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
